Earnings Feed
Start Free
BICYCLE THERAPEUTICS PLC·4

Jul 7, 5:00 PM ET

Perry Jennifer Scott 4

Research Summary

AI-generated summary

Updated

Bicycle Therapeutics (BCYC) COO Jennifer Perry Sells Shares

What Happened
Jennifer Scott Perry, Chief Operating Officer of Bicycle Therapeutics plc (BCYC), sold a total of 1,412 shares in open-market transactions on July 2 and July 6, 2026, generating roughly $6,054 in proceeds. Transactions reported:

  • July 2, 2026: 1,036 shares sold at a weighted avg price of $4.27, proceeds ~$4,424.
  • July 6, 2026: 43 shares sold at a weighted avg price of $4.31, proceeds ~$185.
  • July 6, 2026: 333 shares sold at $4.34, proceeds ~$1,445.
    These were sales (not purchases); part of the activity includes a mandated sell-to-cover for tax withholding and a preplanned sale under a Rule 10b5-1 plan.

Key Details

  • Transaction dates and prices:
    • 2026-07-02: 1,036 shares @ $4.27 (weighted avg; range $4.26–$4.29 per footnote).
    • 2026-07-06: 43 shares @ $4.31 (weighted avg; range $4.30–$4.31 per footnote).
    • 2026-07-06: 333 shares @ $4.34 (reported as executed under a Rule 10b5-1 plan).
  • Total proceeds: ≈ $6,054.
  • Footnotes of note:
    • F1: The July 2 sale represents a required "sell-to-cover" to satisfy statutory tax withholding related to RSU vesting (not a discretionary sale).
    • F2/F3: Prices for the 1,036- and 43-share lots are weighted averages across multiple executions; the filer can provide detailed breakouts on request.
    • F4: One July 6 sale was made pursuant to a Rule 10b5-1 trading plan adopted March 27, 2025 (preplanned).
  • Shares owned after the transactions: not disclosed in the provided excerpt of the filing.
  • Filing date: Form filed July 7, 2026. Form 4s are generally required within two business days of a transaction; the filing includes trades on July 2 and July 6 (check the full EDGAR filing for any timeliness notes).

Context

  • Sell-to-cover transactions (F1) are routine to satisfy tax withholding when RSUs vest and are generally not considered discretionary insider selling.
  • Sales executed under a 10b5-1 plan (F4) are preplanned and do not necessarily reflect current views by the insider.
  • For a full view (ownership after the trades, exact per-trade price breakdowns, and any timeliness annotations), consult the complete Form 4 on SEC EDGAR.